
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Jupiter Neurosciences, Inc. Common Stock (JUNS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: JUNS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 57.65% | Avg. Invested days 51 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 200.22M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.51 - 19.51 | Updated Date 05/11/2025 |
52 Weeks Range 0.51 - 19.51 | Updated Date 05/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 202546214 | Price to Sales(TTM) - |
Enterprise Value 202546214 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 31000000 | Shares Floating - |
Shares Outstanding 31000000 | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Jupiter Neurosciences, Inc. Common Stock
Company Overview
History and Background
Jupiter Neurosciences, Inc. is a pharmaceutical company focused on the development of therapies for neurological diseases. Founded in 2015, it has been focused on developing a new treatment for Mucopolysaccharidosis Type III (MPS III), also known as Sanfilippo syndrome, and other neurological conditions.
Core Business Areas
- Neurological Disease Therapies: Development of therapeutics for neurological diseases, focusing on MPS III and other indications.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure is typical of a biotech firm, with departments dedicated to research, development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- JOTROLu2122: JOTROLu2122 is Jupiter Neurosciencesu2019 product candidate under development for the potential treatment of Mucopolysaccharidosis Type III (MPS III) (Sanfilippo syndrome). No market share is established yet as the product is still under development. Competitors would be gene therapy approaches such as those from Lysogene, although JOTROL targets neuroinflammation rather than directly addressing the genetic defect.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurological diseases is characterized by high unmet needs, significant research and development investment, and a complex regulatory landscape. There is increasing focus on rare diseases, as well as more common neurological conditions.
Positioning
Jupiter Neurosciences is positioned as a company specializing in neurological diseases, with a focus on repurposing drugs to make therapeutics for a new indication. Its competitive advantage lies in its drug development strategy and specific target indications.
Total Addressable Market (TAM)
The TAM for neurological disease therapies is substantial and expected to grow, reaching billions of dollars annually. Jupiter Neurosciences is positioned to capture a portion of this market with their MPS III product and future products, should they be approved. Precise TAM estimates depend on the specific diseases targeted.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Focus on unmet medical needs
- Experienced management team
- Existing drugs may already have certain FDA approvals, allowing for a faster route to approval
Weaknesses
- Limited financial resources
- Dependence on a few key pipeline products
- Clinical trial risks
- Regulatory hurdles
Opportunities
- Partnerships and collaborations
- Expansion into new therapeutic areas
- Fast track regulatory pathways
- Orphan drug designation benefits
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- LLY (Eli Lilly and Company)
- BMY (Bristol-Myers Squibb)
- Lysogene (Currently not traded on a major US exchange but is a competitor)
Competitive Landscape
Jupiter Neurosciences faces competition from larger pharmaceutical companies with established pipelines and resources. Its competitive advantage lies in its focus on neurological diseases and a particular therapeutic approach, as well as its speed to market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to pipeline advancement and clinical trial progress.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives would include the ongoing clinical trial of JOTROLu2122.
Summary
Jupiter Neurosciences is an early-stage pharmaceutical company targeting neurological diseases. The company's success is contingent on the clinical trial results and regulatory approval of its primary drug candidate. It faces significant competition from larger companies with deeper resources. Its focused approach and novel strategy offer potential upside, but the company is highly speculative and carries substantial risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. The information provided is based on publicly available data, which may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jupiter Neurosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2024-12-03 | Co-Founder, CEO & Chairman of the Board Mr. Christer Rosen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://jupiterneurosciences.com |
Full time employees 4 | Website https://jupiterneurosciences.com |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.